Program
vedolizumab
Also written as “Vedolizumab”, “Vedolizumab IV” and “Vedolizumab SC”.
Its studies are mostly in Colitis, Ulcerative · Crohn Disease · Pouchitis · Melanoma · Cholangitis, Sclerosing, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Takeda | 5112 open or running | phase 4since Sep 23, 2015 | Feb 11, 2008 | May 1, 2027phase 4 · NCT06581328 |
| AbbVie | 11 open or running | phase 3since Mar 12, 2025 | Mar 12, 2025 | Aug 2027phase 3 · NCT06880744 |
Also a collaborator on its studies: takeda-development-center-americas-inc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 33 studies since Feb 11, 2008.
- Aug 30, 2018Phase 3 study in Hematopoietic Stem CellsTakeda · NCT03657160 · 343 enrolled · United States, Argentina, Australia and more
- May 10, 20194 phase 1 studies in Healthy VolunteersTakeda · NCT03949621, NCT03948581, NCT03961308 and 1 more
- Feb 2, 2021Phase 3 study in Colitis, UlcerativeTakeda · NCT04738942 · 56 enrolled · Japan
- Mar 1, 20212 phase 3 studiesTakeda · NCT04779320, NCT04779307
- Mar 15, 2021Phase 4 study in Colitis, UlcerativeTakeda · NCT04804540 · 150 enrolled · India
- Jun 30, 2022Phase 3 study in Colitis, UlcerativeTakeda · NCT05442567 · 240 planned · United States, Australia, Belgium and more
- Apr 20, 2023Phase 3 study in Crohn DiseaseTakeda · NCT05837897 · 408 planned · China
- Sep 13, 2023Phase 4 study in Crohn DiseaseTakeda · NCT06045754 · 50 enrolled · United States, Canada
- Oct 17, 2023Phase 3 study in Colitis, UlcerativeTakeda · NCT06100289 · 70 planned · United States, Belgium, Bulgaria and more
- Oct 18, 2023Phase 4 study in Colitis, UlcerativeTakeda · NCT06095128 · 60 enrolled · United States, Canada
- Jan 19, 2024Phase 3 study in Crohn DiseaseTakeda · NCT06227910 · 396 planned · United States, Austria, Belgium and more
- May 3, 20242 phase 3 studiesTakeda · NCT06405087, NCT06443502
- Aug 30, 2024Phase 4 study in Colitis, UlcerativeTakeda · NCT06581328 · 200 planned · United States
- Mar 12, 2025AbbVie's first study: phase 3 study in Colitis, UlcerativeNew to AbbVieAbbVie · NCT06880744 · 573 enrolled · United States, Austria, Bulgaria and more
Ahead
- May 1, 2027Primary completion: phase 4 study in Colitis, UlcerativeTakeda · NCT06581328
- Jun 8, 2027Primary completion: phase 3 study in Crohn DiseaseTakeda · NCT06227910
- Jun 28, 2027Primary completion: phase 4 study in Crohn DiseaseTakeda · NCT06045754
- Jul 9, 2027Primary completion: phase 4 study in Colitis, UlcerativeTakeda · NCT06095128
TargetBeta
“Integrin alpha-4/beta-7 inhibitor”ChEMBL 37, by rule
Studies
All 52 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06880744Colitis, Ulcerative · United States, Austria, Bulgaria and more | 3 | Active, not recruiting | AbbVie | Aug 2027 | 573 |
| NCT06581328Colitis, Ulcerative · United States | 4 | Recruiting | Takeda | May 1, 2027 | 200 |
| NCT06443502Pouchitis · Belgium, Croatia, Czechia and more | 3 | Recruiting | Takeda | Jan 31, 2030 | 30 |
| NCT06405087Colitis, Ulcerative · United States, Belgium, Bulgaria and more | 3 | Recruiting | Takeda | Aug 12, 2030 | 70 |
| NCT06227910Crohn Disease · United States, Austria, Belgium and more | 3 | Recruiting | Takeda | Jun 8, 2027 | 396 |
| NCT06095128Colitis, Ulcerative · United States, Canada | 4 | Active, not recruiting | Takeda | Jul 9, 2027 | 60 |
| NCT06100289Colitis, Ulcerative · United States, Belgium, Bulgaria and more | 3 | Recruiting | Takeda | May 16, 2028 | 70 |
| NCT06045754Crohn Disease · United States, Canada | 4 | Active, not recruiting | Takeda | Jun 28, 2027 | 50 |
| NCT05837897Crohn Disease · China | 3 | Recruiting | Takeda | Mar 8, 2030 | 408 |
| NCT05442567Colitis, Ulcerative · United States, Australia, Belgium and more | 3 | Recruiting | Takeda | Feb 7, 2033 | 240 |
| NCT04804540Colitis, Ulcerative · India | 4 | Completed | Takeda | Feb 2, 2024 | 150 |
| NCT04779320Crohn Disease · United States, Australia, Belgium and more | 3 | Recruiting | Takeda | Sep 13, 2027 | 120 |
| NCT04779307Colitis, Ulcerative · United States, Australia, Belgium and more | 3 | Completed | Takeda | Jul 1, 2025 | 121 |
| NCT04738942Colitis, Ulcerative · Japan | 3 | Active, not recruiting | Takeda | May 30, 2025 | 56 |
| NCT03961308Healthy Volunteers · United States | 1 | Completed | Takeda | Oct 20, 2018 | 204 |
| NCT03961295Healthy Volunteers · United States | 1 | Completed | Takeda | Jul 14, 2018 | 24 |
| NCT03949621Healthy Volunteers · United States | 1 | Completed | Takeda | Jul 2, 2018 | 24 |
| NCT03948581Healthy Volunteers · United States | 1 | Completed | Takeda | Aug 14, 2018 | 102 |
| NCT03657160Hematopoietic Stem Cells · United States, Argentina, Australia and more | 3 | Completed | Takeda | Feb 7, 2022 | 343 |
| NCT03329209Colitis, Ulcerative · China | 1 | Completed | Takeda | Jul 26, 2018 | 16 |
| NCT03234907Crohn Disease · China | 3 | Completed | Takeda | Aug 14, 2020 | 215 |
| NCT03221036Moderately to Severely Active Ulcerative Colitis · China | 3 | Active, not recruiting | Takeda | Sep 24, 2027 | 392 |
| NCT03196427Colitis, Ulcerative · United States, France, Hungary and more | 2 | Completed | Takeda | Apr 3, 2025 | 59 |
| NCT03138655Colitis, Ulcerative · United States, Belgium, Canada and more | 2 | Completed | Takeda | Mar 31, 2020 | 89 |
| NCT03035058Cholangitis, Sclerosing | 3 | Withdrawn | Takeda | Sep 2020 | 0 |
| NCT03029143Colitis, Ulcerative · United States, Canada | 4 | Completed | Takeda | Oct 16, 2020 | 278 |
| NCT02993783Allogeneic Hematopoietic Stem Cell Transplantation · United States, Belgium, France and more | 2 | Terminated | Takeda | May 9, 2018 | 17 |
| NCT02913508Colitis, Ulcerative | 2 | Withdrawn | Takeda | Dec 2015 | 0 |
| NCT02790138Pouchitis · United States, Belgium, Canada and more | 4 | Completed | Takeda | Jun 11, 2020 | 102 |
| NCT02764762Crohn Disease · United States, Canada | 4 | Completed | Takeda | Sep 22, 2020 | 55 |
| NCT02760615Colitis, Ulcerative · United States | 4 | Withdrawn | Takeda | Aug 1, 2020 | 0 |
| NCT02743806Colitis, Ulcerative · Australia, Bulgaria, Czechia and more | 4 | Terminated | Takeda | Jan 3, 2023 | 331 |
| NCT02728895Allogeneic Hematopoietic Stem Cell Transplantation · United States | 1 | Completed | Takeda | Jul 10, 2018 | 24 |
| NCT02723006Melanoma · United States | 1 | Terminated | Takeda | May 11, 2018 | 22 |
| NCT02630966Crohn Disease · United States, Canada, France and more | 4 | Completed | Takeda | Sep 4, 2018 | 34 |
| NCT02620046Colitis, Ulcerative · United States, Argentina, Australia and more | 3 | Completed | Takeda | Jun 12, 2024 | 746 |
| NCT02611830Colitis, Ulcerative · United States, Argentina, Australia and more | 3 | Completed | Takeda | May 30, 2018 | 383 |
| NCT02611817Crohn Disease · United States, Australia, Belgium and more | 3 | Completed | Takeda | May 6, 2019 | 644 |
| NCT02559713Colitis, Ulcerative · United States | 4 | Completed | Takeda | Feb 22, 2019 | 11 |
| NCT02497469Colitis, Ulcerative · United States, Argentina, Australia and more | 3 | Completed | Takeda | Sep 26, 2018 | 771 |
| NCT02425111Crohn Disease · United States, Belgium, Canada and more | 3 | Completed | Takeda | Jun 2, 2017 | 101 |
| NCT02163421Healthy · United Kingdom | 1 | Completed | Takeda | Dec 2014 | 48 |
| NCT02039505Colitis, Ulcerative · Japan | 3 | Completed | Takeda | Feb 27, 2018 | 292 |
| NCT02038920Crohn Disease · Japan | 3 | Completed | Takeda | Jan 25, 2019 | 157 |
| NCT01981616Inflammatory Bowel Diseases · United Kingdom | 1 | Completed | Takeda | May 2012 | 127 |
| NCT01224171Crohn Disease · United States, Canada | 3 | Completed | Takeda | Feb 2012 | 416 |
| NCT01177228Colitis, Ulcerative | 2 | Completed | Takeda | Jun 2008 | 47 |
| NCT00790933Colitis, Ulcerative · United States, Australia, Belgium and more | 3 | Completed | Takeda | Oct 31, 2017 | 2,243 |
| NCT00783718Colitis, Ulcerative · United States, Canada, Puerto Rico | 3 | Completed | Takeda | Dec 2011 | 895 |
| NCT00783692Crohn Disease · United States, Canada, Puerto Rico | 3 | Completed | Takeda | Mar 2012 | 1,116 |
| NCT00655135Crohn Disease | 2 | Completed | Takeda | Jun 2002 | 185 |
| NCT00619489Colitis, Ulcerative · Canada | 2 | Completed | Takeda | Mar 2010 | 72 |
How it is read
Names in the registry
- “Vedolizumab”, 27 entries
- “Vedolizumab IV”, 9 entries
- “Vedolizumab SC”, 9 entries
- “vedolizumab”, 5 entries
- “Vedolizumab 108 mg SC”, 1 entry
Conditions, from the studies’ own filings
- Colitis, Ulcerative, 26 studies
- Crohn Disease, 13 studies
- Pouchitis, 2 studies
- Melanoma, 1 study
- Cholangitis, Sclerosing, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.